Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1006 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Helsinn widens licensing deal with Riemser

The new product is a fixed-dose combination (in both oral and IV forms) containing netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron. The agreement allows Helsinn to take

FDA approves Lannett Loxapine Capsules

Lannett’s Loxapine Capsules, 5mg, 10mg, 25mg and 50mg are the generic version of Watson Pharmaceuticals’ Loxitane Capsules, 5mg, 10mg, 25mg and 50mg. The company expects to start supplying

Chinese MOA licenses Sinovac to produce RabEnd

The production license follows the issuance of the New Animal Drug Certificate and the Certificate of Good Manufacturing Practices for Animal Drugs (GMP Certificate) by the MOA. Sinovac

Antioxidant supplements witness soaring demand

Antioxidants can neutralize harmful by-products of human metabolism, as certain free radical created in the process can be hazardous to cell health. According to the company, antioxidants help